September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
May 2011 in “MOspace Institutional Repository (University of Missouri)” Finasteride at 1 mg daily doesn't help hair loss in postmenopausal women and has similar side effects to a placebo.
1 citations
,
June 2019 in “Current Developments in Nutrition” S-equol supplements significantly reduced menopausal symptoms in most women.
April 2010 in “Nature Reviews Urology”
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
19 citations
,
July 2019 in “Journal of Endocrinology” GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.
34 citations
,
January 1995 in “The Journal of Clinical Endocrinology and Metabolism”
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
90 citations
,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
53 citations
,
November 2014 in “International Journal of Oncology” Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
15 citations
,
August 2016 in “Current Urology Reports” Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.
December 2023 in “Reactions weekly” January 2023 in “Reactions Weekly” May 2022 in “Reactions Weekly” April 2026 in “Reactions Weekly” January 2026 in “Elsevier eBooks” December 2024 in “Reactions Weekly”